Edgen Stock·Sep 12 2025, 04:00戻る
戻る
Avidity Biosciences Advances Del-Zota Towards Accelerated FDA Approval for Duchenne Muscular Dystrophy
Edgen Stock·Sep 12 2025, 04:00
[1] Avidity Biosciences: 'Strong Buy' Based On Accelerated Approval Filing For Del-Zota (RNA)[2] Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha[3] KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results